2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-145112
    AChE-IN-3 2713548-95-7 99.46%
    AChE-IN-3 shows moderate inhibitory activity against AChE and strong NO inhibitory activity with an EC50 of 0.57 μM.
    AChE-IN-3
  • HY-145196
    RTICBM-189 551909-15-0 99.73%
    RTICBM-189 is a potent, brain-penetrant allosteric modulator of the cannabinoid type-1 (CB1) receptor with a pIC50 of 7.54 in Ca2+ mobilization assay. RTICBM-189 has pIC50s of 5.29 and 6.25 for hCB1 and mCB1, respectively. RTICBM-189 significantly and selectively attenuates the reinstatement of the addictive agent-seeking behavior in rats.
    RTICBM-189
  • HY-145250
    NK1 receptor antagonist 2 579475-17-5
    NK1 receptor antagonist 2 is a NK1 receptor antagonist. NK1 receptor antagonist 2 can be used for the research of tinnitus and hearing loss.
    NK1 receptor antagonist 2
  • HY-145256
    GABAA receptor agent 4 2035203-91-7 98%
    GABAA receptor agent 4 (compound 1e) is a potent γ-GABAAR antagonist with an Ki of 0.18 µM. GABAA receptor agent 4 efficiently rescues inhibition of T cell proliferation. GABAA receptor agent 4 has the immunomodulatory potential.
    GABAA receptor agent 4
  • HY-145257
    GABAA receptor agent 5 1808389-92-5 98%
    GABAA receptor agent 5 (compound 018) is a potent γ-GABAAR antagonist with an Ki of 0.020 µM. GABAA receptor agent 5 shows γ-GABAAR antagonist activity with low cellular membrane permeability.
    GABAA receptor agent 5
  • HY-145258
    GABAA receptor agent 6 1808463-81-1 98%
    GABAA receptor agent 6 (compound 2027) is a potent γ-GABAAR antagonist with an Ki of 0.56 µM. GABAA receptor agent 6 shows γ-GABAAR antagonist activity with low cellular membrane permeability.
    GABAA receptor agent 6
  • HY-145294
    ROCK2-IN-5 3031515-48-4 98%
    ROCK2-IN-5 (compound 1d) is a hybrid compound containing structural fragments of the Rho kinase inhibitor fasudil and the NRF2 inducers caffeic and ferulic acids. ROCK2-IN-5 has good multitarget profile and good tolerability. ROCK2-IN-5 has the potential for thr research of Amyotrophic lateral sclerosis (ALS) with a SOD1 mutation.
    ROCK2-IN-5
  • HY-145308
    Heterobivalent ligand-1 2888568-58-7 98%
    Heterobivalent ligand-1 (compound 26) is a heterobivalent ligand for the Adenosine A 2A-dopamine D 2 receptor heteromer (KDB1 A2AR=2.1 nM, KDB1 D2R= 0.13 nM).
    Heterobivalent ligand-1
  • HY-145318
    LRRK2-IN-3 2641054-60-4 98%
    LRRK2-IN-3 (compoubd 24) is a potent, selective, orally active and brain-penetrant inhibitor LRRK2, with IC50 of 2.6 nM in human PBMCs. LRRK2-IN-3 can be used for the research of Parkinson's disease.
    LRRK2-IN-3
  • HY-145345
    BACE1-IN-6 2079945-75-6 98%
    BACE1-IN-6 is a BACE1 inhibitor with an IC50 value of 1.5 nM.
    BACE1-IN-6
  • HY-145369
    DS34942424 2967655-39-4 98%
    DS34942424 is an orally potent analgesic without mu opioid receptor agonist activity.
    DS34942424
  • HY-145370
    GluN2B receptor modulator-1 2222010-71-9 98%
    GluN2B receptor modulator-1 is a selective GluN2B negative allosteric modulator with an IC50 value of 31 nM.
    GluN2B receptor modulator-1
  • HY-145372
    γ-Secretase modulator 10 2694817-84-8 98%
    γ-Secretase modulator 10 is a novel γ-secretase modulator.
    γ-Secretase modulator 10
  • HY-14539B
    Clozapine dihydrochloride 2711603-38-0 98%
    Clozapine (HF 1854) dihydrochloride is an antipsychotic used for the research of schizophrenia. Clozapine has high affinity for a number of neuroreceptors. Clozapine is a potent antagonist of dopamine D2 with a Ki of 75 nM. Clozapine inhibits the muscarinic M1 receptor and serotonin 5HT2A receptor with Kis of 9.5 nM and 4 nM, respectively. Clozapine is also a potent and selective agonist at the muscarinic M4 receptor (EC50=11 nM).
    Clozapine dihydrochloride
  • HY-14542C
    Ziprasidone mesylate 185021-64-1 98%
    Ziprasidone (CP-88059) mesylate is an orally active combined 5-HT and dopamine receptor antagonist. Ziprasidone mesylate has affinities for Rat D2 (Ki=4.8 nM), 5-HT2A (Ki=0.42 nM) and 5-HT1A (Ki=3.4 nM).
    Ziprasidone mesylate
  • HY-14542S
    Ziprasidone-d8 1126745-58-1 98%
    Ziprasidone-d88 is deuterium labeled Ziprasidone, which is a combined 5-HT (serotonin) and dopamine receptor antagonist which exhibits potent effects of antipsychotic activity.
    Ziprasidone-d8
  • HY-14545B
    SEP-4199 2974362-88-2 98%
    SEP4199 is an orally active 5-HT7 receptor ligand, with a Ki value of 66 nM for human 5-HT7R and 16 nM for human D2R. SEP4199 mediates antidepressant effects. SEP4199 is applicable for the research of bipolar depression.
    SEP-4199
  • HY-145475
    Nervonoyl ethanolamide 887405-21-2 98%
    Nervonoyl ethanolamide (NEA) is an endogenous cannabinoid that can act as a presynaptic and postsynaptic neuromodulator. Nervonoyl ethanolamide can also be used in the research of inflammation.
    Nervonoyl ethanolamide
  • HY-145482
    W36017 21236-54-4
    W3601 is the impurity of Lidocaine. W3601 exhibits nerve blocking activity with the pKa of 7.4.
    W36017
  • HY-14551B
    (S)-Osanetant 182621-58-5 99.25%
    (S)-Osanetant is the S-enantiomer of Osanetant. Osanetant (SR142801) is a selective NK3 receptor antagonist. Osanetant produces anxiolytic- and antidepressant-like effects and is researched for schizophrenia.
    (S)-Osanetant
Cat. No. Product Name / Synonyms Application Reactivity